While a marginal delay in treatment initiation due to PD-related care-access challenges might explain a slight shift in the timing of the first injection or injection frequency, it does not explain a delay of several years for a condition necessitating urgent and singular anti-VEGF treatment. This evidence concerns the gene VEGFA and Parkinson disease.